Leerink Swann reaffirmed their outperform rating on shares of Kura Oncology Inc. (NASDAQ:KURA) in a report released on Thursday morning. The brokerage currently has a $15.00 price objective on the stock.
A number of other analysts also recently weighed in on KURA. Oppenheimer Holdings Inc. reiterated an outperform rating and issued a $16.00 price target on shares of Kura Oncology in a research report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Kura Oncology from a hold rating to a buy rating and set a $3.75 target price on the stock in a report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $14.15.
Kura Oncology (NASDAQ:KURA) traded down 0.35% during mid-day trading on Thursday, hitting $5.74. The stock had a trading volume of 3,270 shares. The company’s market cap is $107.58 million. Kura Oncology has a one year low of $2.50 and a one year high of $25.00. The company has a 50 day moving average price of $6.15 and a 200-day moving average price of $4.19.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. Equities analysts expect that Kura Oncology will post ($1.58) earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Kura Oncology stock. Minerva Advisors LLC bought a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent filing with the SEC. The firm bought 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned approximately 1.96% of Kura Oncology as of its most recent filing with the SEC. 43.63% of the stock is currently owned by institutional investors.
About Kura Oncology